Clovis Oncology secures EC approval for Rubraca’s new indication in ovarian cancer treatment

pharmanewsdaily- January 26, 2019 0

In a major win for Clovis Oncology, the European Commission (EC) has granted approval for an expanded indication for its cancer drug, Rubraca (rucaparib). This ... Read More

Refined white sugar may result in development of ovarian cancer in women

pharmanewsdaily- March 13, 2018 0

World Health Organisation says that refined white sugar can contribute to adverse health effects and it should be restricted in diet by 10 to 20 ... Read More

AstraZeneca’s Lynparza shows promising results in phase 3 ovarian cancer trial

pharmanewsdaily- March 18, 2017 0

AstraZeneca has reported significant findings from its phase 3 trial, SOLO-2, for its ovarian cancer drug Lynparza (olaparib), demonstrating considerable improvement in survival chances for ... Read More

1213 / 13 Posts